** Shares of Lumos Diagnostics LDX.AX more than double in value to A$0.080
** Stock posts its biggest intraday pct gain since July 2023
** Healthcare tech co signs U.S. distribution and supply agreement for FebriDx valued at up to $317 million
** FebriDx is a rapid point of care test that helps clinicians differentiate between bacterial and non-bacterial acute respiratory infections through a fingerstick blood sample
** Agreement signed with Hong Kong-headquartered PHASE Scientific International
** About 15.8 million shares change hands, compared with the 30-day average volume of 663,247
** YTD, shares up 108.6%
(Reporting by Nichiket Sunil in Bengaluru)
((Nichiket.Sunil@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。